|Day Low/High||35.97 / 37.04|
|52 Wk Low/High||33.17 / 79.17|
- Maximum Hemoglobin Increases >1.0 g/dL Observed in 50% of Patients in Core Period, Among Whom the Mean Maximum Hemoglobin Increase was 3.
CAMBRIDGE, Mass., Aug.
Strong Topline Performance for IDH Inhibitors: TIBSOVO ® Net Revenue Increased 50% from Q1 2019 to $13.
CAMBRIDGE, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc.
Let's see if this new name is worth buying.
Data and industry conferences will likely be catalysts for shares in the space.
MTAP Deletion Present in Approximately 15 Percent of All Cancers
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.